Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Mai 2024 - 12:32PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca to manufacture ADCs in Singapore
20 May 2024
AstraZeneca plans $1.5 billion manufacturing facility
for antibody drug conjugates (ADCs) in Singapore
Operationally ready by 2029, it will be the Company's
first-ever facility to cover the full manufacturing process for
ADCs
AstraZeneca intends to build a $1.5 billion manufacturing facility
in Singapore for antibody drug conjugates (ADCs), enhancing global
supply of its ADC portfolio. ADCs are next-generation treatments
that deliver highly potent cancer-killing agents directly to cancer
cells through a targeted antibody.
The planned greenfield facility, supported by the Singapore
Economic Development Board (EDB), will be AstraZeneca's first
end-to-end ADC production site, fully incorporating all steps of
the manufacturing process at a commercial scale. Manufacturing of
ADCs is a multi-step process that comprises antibody production,
synthesis of chemotherapy drug and linker, conjugation of
drug-linker to the antibody, and filling of the completed ADC
substance.
Png Cheong Boon, Chairman, EDB said: "We welcome AstraZeneca's
decision to establish a manufacturing presence in Singapore for the
first time. It will also be a first for AstraZeneca - an end-to-end
manufacturing facility for novel antibody drug conjugates that
enables precision therapy for cancer. This greenfield investment is
a strong show of confidence in Singapore's biopharmaceutical
manufacturing capabilities and talent, strengthens our ecosystem in
supporting the development and manufacturing of precision
medicines, and creates meaningful jobs and economic opportunities
for Singapore. We look forward to a successful partnership with
AstraZeneca."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
"AstraZeneca has built an industry-leading portfolio of cancer
medicines including antibody drug conjugates which have shown
enormous potential to replace traditional chemotherapy for patients
across many settings. Singapore is one of the world's most
attractive countries for investment given its reputation for
excellence in complex manufacturing, and I am excited for
AstraZeneca to locate our $1.5 billion ADC manufacturing facility
in the country."
AstraZeneca has a broad portfolio of in-house ADCs including six
wholly owned ADCs in the clinic and many more in preclinical
development.
As part of AstraZeneca's commitment to driving sustainability in
healthcare, the Company will work with Singapore's government and
other partners on green solutions for the ADC facility. This
facility will be designed to emit zero carbon from its first day of
operations.
AstraZeneca aims to begin design and construction of the
manufacturing facility by the end of 2024, with targeted
operational readiness from 2029.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
20 May 2024
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
AstraZeneca (NASDAQ:AZN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024